0001562180-20-002990.txt : 20200413 0001562180-20-002990.hdr.sgml : 20200413 20200413165556 ACCESSION NUMBER: 0001562180-20-002990 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200409 FILED AS OF DATE: 20200413 DATE AS OF CHANGE: 20200413 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reeve Emma CENTRAL INDEX KEY: 0001680329 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38584 FILM NUMBER: 20789190 MAIL ADDRESS: STREET 1: C/O PAREXEL INTERNATIONAL CORPORATION STREET 2: 195 WEST STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CONSTELLATION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001434418 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-714-0555 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-04-09 false 0001434418 CONSTELLATION PHARMACEUTICALS INC CNST 0001680329 Reeve Emma C/O CONSTELLATION PHARMACEUTICALS, INC. 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142 false true false false Chief Financial Officer Common Stock 2020-04-09 4 M false 111.00 8.76 A 111.00 D Common Stock 2020-04-09 4 S false 111.00 35.0179 D 0.00 D Common Stock 2020-04-09 4 M false 589.00 7.60 A 589.00 D Common Stock 2020-04-09 4 S false 589.00 35.0179 D 0.00 D Stock Option (right to buy) 8.76 2020-04-09 4 M false 111.00 0.00 D 2029-03-06 Common Stock 111.00 85389.00 D Stock Option (right to buy) 7.60 2020-04-09 4 M false 589.00 0.00 D 2028-03-05 Common Stock 589.00 20611.00 D These trades were made pursuant to a Rule 10b5-1 trading plan. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.075. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This option was granted on March 7, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments through March 7, 2023. This option was granted on March 6, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 6, 2022. /s/ Emma Reeve 2020-04-13